Can Leqvio and Shingrix Be Given on the Same Day?
Yes, Leqvio (inclisiran) can be administered on the same day as Shingrix (recombinant zoster vaccine), as there are no contraindications to co-administering an inactivated vaccine with a non-vaccine medication like Leqvio.
Rationale for Co-Administration
Vaccine Classification and Safety Principles
Shingrix is an inactivated recombinant vaccine, not a live vaccine, which means it can be safely co-administered with other inactivated vaccines and medications without interference in immune response 1.
General vaccination principles support simultaneous administration of inactivated vaccines with other inactivated vaccines or medications, as there is no evidence that inactivated vaccines interfere with immune responses when given concomitantly 2.
Evidence for Shingrix Co-Administration with Other Vaccines
The FDA label for Shingrix demonstrates robust safety and immunogenicity data when co-administered with multiple vaccines:
Influenza vaccine (FLUARIX QUADRIVALENT): No evidence of interference in immune response to either vaccine when given simultaneously 1.
Pneumococcal vaccines (PNEUMOVAX 23 and PREVNAR 13): Co-administration showed no interference in immune responses, though more frequent adverse reactions were reported with PPSV23 2, 1.
Tdap vaccine (BOOSTRIX): Co-administration was safe with maintained immune responses (except for one pertussis antigen of unclear clinical significance) 1.
COVID-19 mRNA vaccine: A 2024 systematic review confirmed that co-administration of Shingrix with routine adult vaccines, including COVID-19 vaccines, does not significantly alter reactogenicity, immunogenicity, or safety 3.
Leqvio-Specific Considerations
Leqvio is a small interfering RNA (siRNA) medication, not an immunosuppressive agent or vaccine, administered subcutaneously every 6 months for cholesterol management.
There are no known drug interactions between Leqvio and vaccines, as Leqvio's mechanism of action (inhibiting PCSK9 synthesis in hepatocytes) does not affect immune system function.
No immunosuppression concerns: Unlike the immunomodulators discussed in IBD guidelines 4 or rheumatology guidelines 5, Leqvio does not suppress immune function and therefore poses no contraindication to vaccination.
Practical Administration Guidelines
Injection Site Management
Administer vaccines in different anatomical sites (e.g., Shingrix in one deltoid, Leqvio in the other deltoid or abdomen) to minimize local reactions and allow proper assessment of any adverse events 1.
Shingrix should be given intramuscularly in the deltoid region 1.
Leqvio is administered subcutaneously in the abdomen or upper arm.
Timing Considerations
Same-day administration is acceptable and recommended to improve vaccination coverage and reduce missed opportunities 2, 3.
No waiting period is required between Leqvio and Shingrix administration, as neither agent affects the other's efficacy or safety profile.
Important Caveats
Reactogenicity Awareness
Shingrix is known for significant reactogenicity: Myalgia (38-64%), fatigue, and injection site reactions are common 1, 3.
Counsel patients about expected side effects to prevent misattribution of Shingrix reactions to Leqvio, which could affect future medication adherence 2.
Fever and systemic symptoms occur more frequently with Shingrix than with most other vaccines, particularly when co-administered with pneumococcal vaccines 2, 1.
Patient-Specific Factors
Pregnancy is a contraindication to Shingrix and should be ruled out in women of childbearing potential 6.
Immunocompromised patients can receive Shingrix (unlike live zoster vaccine), as it is a recombinant vaccine 4, 7, 6.
Complete the two-dose Shingrix series (second dose at 2-6 months) for optimal protection, as tolerability concerns are a leading reason for series non-completion 8.
Documentation
- Record both administrations separately with specific injection sites documented to facilitate adverse event monitoring and ensure proper follow-up for the second Shingrix dose 1.